Biocon’s arm inks MoU with MEM for Graduate Program & Talent Management

Biocon Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 532523 | NSE: BIOCON

14 Sep 2012 Evaluate

Biocon India’s wholly owned subsidiary - Biocon Sdn Bhd, Malaysia and Manipal Education Malaysia (MEM), have entered into a Memorandum of Understanding (MoU) to collaborate for the development of human capital for the Biotechnology industry in Malaysia.

The MoU outlines the creation of an Internship Programme and Graduate Employment Programme for the admission of MIU’s students and graduates to Biocon’s Malaysia facility for training and employment. Through the MoU, Manipal International University’s (MIU) and Biocon will also be collaborating in the development of specialised training and skills enhancement to ensure that graduates from relevant disciplines are equipped and ready for entry into Biocon Malaysia. The MoU further provides for MEM to conduct employee training programmes at Biocon Malaysia facility.

Biocon, India's largest biotechnology company is a fully-integrated, innovation-driven healthcare enterprise with strategic focus on biopharmaceuticals and research services. The company is developing its manufacturing and R&D facility in Iskandar Malaysia, Johor with an investment of over RM500 million, which will be operational in 2014. Together with its team of over 6000 employees Biocon delivers affordable solutions to partners and customers in over 75 countries across the globe.

Manipal Education Malaysia (MEM) provides a suite of education facilities and services. It is the parent company of Manipal International University (MIU). MEM provides a suite of education facilities and services. Its flagship project is the Manipal International University (MIU). MIU’s interim campus is in Kelana Jaya whilst its 140 acre campus, costing over RM650 million is being developed in Nilai, Negeri Sembilan. The Nilai campus will be operational by the end of this year.

Biocon is Asia’s leading R&D based Biotechnology Company. It produces anti-diabetic agents like Acarbose, Pioglitazone, Repaglinides and Rosiglitazone. In the biological segment, it produces Insulin, Erythropoietin (EPO), Filgrastim (GCSF), Streptokinase and Monoclonal Antibodies.

Biocon Share Price

380.55 -2.05 (-0.54%)

08-May-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1847.30
Dr. Reddys Lab	1293.25
Cipla	1347.70
Zydus Lifesciences	938.90
Lupin	2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.